Augmented cytotoxicity of hydroxycamptothecin-loaded nanoparticles in lung and colon cancer cells by chemosensitizing pharmaceutical excipients

References

• Acharya S, Dilnawaz F, Sahoo SK. (2009). Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30:5737–50
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Delivery Rev 63:170–83
   PubMed Web of Science ®Google Scholar
• Arias JL, Reddy LH, Couvreur P. (2009). Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target 17:586–98
   PubMed Web of Science ®Google Scholar
• Barzegar-Jalali M. (2008). Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci 11:167–77
   PubMed Web of Science ®Google Scholar
• Basarkar A, Devineni D, Palaniappan R, Singh J. (2007). Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm 343:247–54
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. (2008). Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 130:98–106
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Li Y, et al. (2004). Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226–33
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Miller DW, Kabanov AV. (1999). Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 16:1366–72
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Miller DW, Li S, et al. (2001). Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 296:551–7
   PubMed Web of Science ®Google Scholar
• Betancourt T, Brown B, Brannon-Peppas L. (2007). Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomed 2:219–32
   PubMed Web of Science ®Google Scholar
• Betancourt T, Byrne JD, Sunaryo N, et al. (2009). PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J Biomed Mater Res A 91:263–76
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Sarisozen C, Esendagli G, et al. (2009). Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm 371:170–6
   PubMed Web of Science ®Google Scholar
• Calvo P, Remunan C, Vila Jato JL, Alonso MJ. (1997). Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron emulsions. Colloid Polym Sci 275:46–53
   Web of Science ®Google Scholar
• Chakravarthi SS, Robinson DH. (2011). Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409:111–20
   PubMed Web of Science ®Google Scholar
• Chronopoulou L, Massimi M, Giardi MF, et al. (2013). Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures. Colloids Surf B Biointerfaces 103:310–17
   PubMed Web of Science ®Google Scholar
• Chung TW, Wang SS, Tsai WJ. (2008). Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials 29:228–37
   PubMed Web of Science ®Google Scholar
• Cohen-Sela E, Teitlboim S, Chorny M, et al. (2009). Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity. J Pharm Sci 98:1452–62
   PubMed Web of Science ®Google Scholar
• Collnot E-M, Baldes C, Wempe MF, et al. (2006). Influence of vitamin E TPGS poly (ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 111:35–40
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–33
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, et al. (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17
   PubMed Web of Science ®Google Scholar
• Davaran S, Rashidi MR, Pourabbas B, et al. (2006). Adriamycin release from poly(lactide-coglycolide)-polyethylene glycol nanoparticles: synthesis, and in vitro characterization. Int J Nanomedicine 1:535–9
   PubMed Web of Science ®Google Scholar
• De Campos AM, Sanchez A, Gref R, et al. (2003). The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 20:73–81
   PubMed Web of Science ®Google Scholar
• Derakhshandeh K, Erfan M, Dadashzadeh S. (2007). Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm 66:34–41
   PubMed Web of Science ®Google Scholar
• Devi JS, Bhimba BV, Ratnam K. (2012). In vitro anticancer activity of silver nanoparticles synthesized using the extract of Gelidiella Sp. Int J Pharm Pharm Sci 4:710–15
   Google Scholar
• Devi Kusum V, Bhosale UV. (2009). Formulation and optimization of polymeric nano drug delivery system of acyclovir using 32 full factorial design. Int J Pharm Tech Res 1:644–53
   Google Scholar
• Dong Y, Feng SS. (2007). In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 28:4154–60
   PubMed Web of Science ®Google Scholar
• Feng SS, Mei L, Anitha P, et al. (2009). Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 30:3297–306
   PubMed Web of Science ®Google Scholar
• Feng SS, Mu L, Win KY, Huang G. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 11:413–24
   PubMed Web of Science ®Google Scholar
• Feng SS, Zeng W, Teng Lim Y, et al. (2007). Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomed 2:333–44
   PubMed Web of Science ®Google Scholar
• Gindy ME, Prud'homme RK. (2009). Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 6:865–78
   PubMed Web of Science ®Google Scholar
• GLOBOCAN. (2008). Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. Available from: http://globocan.iarc.fr/factsheet.asp [last accessed 10 March 2013]
   Google Scholar
• Grabovac V, Bernkop-Schnurch A. (2007). Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug Dev Ind Pharm 33:767–74
   PubMed Web of Science ®Google Scholar
• Gu F, Langer R, Farokhzad OC. (2009). Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol 544:589–98
   PubMedGoogle Scholar
• Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. (2008). Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9:435–43
   PubMed Web of Science ®Google Scholar
• Hatefi A, Amsden B. (2002). Camptothecin delivery methods. Pharm Res 19:1389–99
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. (2005). Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16:691–707
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L. (2009). Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 10:836–41
   PubMed Web of Science ®Google Scholar
• Huang M, Khor E, Lim LY. (2004). Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res 21:344–53
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJ. (2002). An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 4:193--205
   Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. (2002). Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82:189–212
   PubMed Web of Science ®Google Scholar
• Khdair A, Handa H, Mao G, Panyam J. (2009). Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur J Pharm Biopharm 71:214–22
   PubMed Web of Science ®Google Scholar
• Kim BS, Kim CS, Lee KM. (2008). The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles. Arch Pharm Res 31:1050–4
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, et al. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15:25–35
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. (2009). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1--18
   Google Scholar
• Kunii R, Onishi H, Machida Y. (2007). Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 67:9–17
   PubMed Web of Science ®Google Scholar
• Kunii R, Onishi H, Ueki K, et al. (2008). Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles. Drug Deliv 15:3–10
   PubMed Web of Science ®Google Scholar
• Mahor A, Alok S, Gupta Y, Jain SK. (2010). Body distribution and stability studies on mitoxantrone loaded solid lipid nanoparticles conjugated with concanavalin-A. Int J Pharm Pharm Sci 2:39–42
   Google Scholar
• Miller DW, Batrakova EV, Kabanov AV. (1999). Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 16:396–401
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Sahoo SK. (2010). Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 15:842–50
   PubMed Web of Science ®Google Scholar
• Morgan MT, Nakanishi Y, Kroll DJ, et al. (2006). Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 66:11913–21
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. (2003). A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86:33–48
   PubMed Web of Science ®Google Scholar
• Nafee N, Taetz S, Schneider M, et al. (2007). Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 3:173–83
   PubMed Web of Science ®Google Scholar
• Nasti A, Zaki NM, de Leonardis P, et al. (2009). Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 26:1918–30
   PubMed Web of Science ®Google Scholar
• Neuzil J, Dong LF, Wang XF, Zingg JM. (2006). Tocopherol-associated protein-1 accelerates apoptosis induced by alpha-tocopheryl succinate in mesothelioma cells. Biochem Biophys Res Commun 343:1113–17
   PubMed Web of Science ®Google Scholar
• Neuzil J, Weber T, Schroder A, et al. (2001a). Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. Faseb J 15:403–15
   PubMed Web of Science ®Google Scholar
• Neuzil J, Weber T, Terman A, et al. (2001b). Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Rep 6:143–51
   PubMed Web of Science ®Google Scholar
• Neuzil J, Zhao M, Ostermann G, et al. (2002). Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem J 362:709–15
   PubMed Web of Science ®Google Scholar
• Pan J, Feng SS. (2008). Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29:2663–72
   PubMed Web of Science ®Google Scholar
• Parveen S, Sahoo SK. (2011). Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 670:372–83
   PubMed Web of Science ®Google Scholar
• Pillai RR, Somayaji SN, Rabinovich M, et al. (2008). Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed Mater 3:034114, 1--7
   Google Scholar
• Prego C, Torres D, Fernandez-Megia E, et al. (2006). Chitosan–PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release 111:299–308
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. (1987a). A simple equation for description of solute release. I. Fickian and non-Fickian release from nonswellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 5:23–36
   Google Scholar
• Ritger PL, Peppas NA. (1987b). A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release 5:37–42
   Google Scholar
• Shah N, Chaudhari K, Dantuluri P, et al. (2009). Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 17:533–42
   PubMed Web of Science ®Google Scholar
• Shaji J, Jain V. (2010). Solid lipid nanoparticles: a novel carrier for chemtherapy. Int J Pharm Pharm Sci 2:8–17
   Google Scholar
• Shenderova A, Burke TG, Schwendeman SP. (1997). Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 14:1406–14
   PubMed Web of Science ®Google Scholar
• Shenderova A, Burke TG, Schwendeman SP. (1999). The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 16:241–8
   PubMed Web of Science ®Google Scholar
• Shu S, Zhang X, Teng D, et al. (2009). Polyelectrolyte nanoparticles based on water-soluble chitosan-poly(L-aspartic acid)-polyethylene glycol for controlled protein release. Carbohydr Res 344:1197–204
   PubMed Web of Science ®Google Scholar
• Song H, Hu H. (2012). Hydroxycamptothecin inhibits proliferation of human lung carcinoma cell line A549 and down-regulates its Bcl-2 gene expression in vitro. Nan Fang Yi Ke Da Xue Xue Bao 32:1341–5
   PubMedGoogle Scholar
• Taetz S, Nafee N, Beisner J, et al. (2009). The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells. Eur J Pharm Biopharm 72:358–69
   PubMed Web of Science ®Google Scholar
• Wang A, Li S. (2008). Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect. BMC Biotechnol 8:46
   PubMed Web of Science ®Google Scholar
• Weiss B, Schaefer UF, Zapp J, et al. (2006). Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility. J Nanosci Nanotechnol 6:3048–56
   PubMed Web of Science ®Google Scholar
• Xie J, Wang CH. (2005). Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm Res 22:2079–90
   PubMed Web of Science ®Google Scholar
• Xu P, Gullotti E, Tong L, et al. (2009). Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 6:190–1
   PubMed Web of Science ®Google Scholar
• Yamagata T, Kusuhara H, Morishita M, et al. (2007). Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 35:1142–8
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Nishiyama Y, Furuta T, et al. (2011). Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 10:1252–63
   PubMed Web of Science ®Google Scholar
• Yang R, Shim WS, Cui FD, et al. (2009a). Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 371:142–7
   PubMed Web of Science ®Google Scholar
• Yang R, Yang SG, Shim WS, et al. (2009b). Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 98:970–84
   PubMed Web of Science ®Google Scholar
• You J, Hu FQ, Du YZ, et al. (2007). High cytotoxicity and resistant-cell reversal of novel paclitaxel loaded micelles by enhancing the molecular-target delivery of the drug. Nanotechnology 18:495101, 1--7
   Google Scholar
• Yu JM, Li YJ, Qiu LY, Jin Y. (2009). Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in vitro and in vivo characterization. J Pharm Pharmacol 61:713–19
   PubMed Web of Science ®Google Scholar
• Yu W, Israel K, Liao QY, et al. (1999). Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res 59:953–61
   PubMed Web of Science ®Google Scholar
• Yu W, Jia L, Wang P, et al. (2008). In vitro and in vivo evaluation of anticancer actions of natural and synthetic vitamin E forms. Mol Nutr Food Res 52:447–56
   PubMed Web of Science ®Google Scholar
• Zaki NM, Al-Barraq A, Hafez MM. (2013). Development of a pharmaceutically optimized nanometric system of a chemotherapeutic drug. Int J Pharm Pharm Sci Vol 5:161–8
   Google Scholar
• Zaki NM, Hafez MM. (2012). Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS PharmSciTech 13:411–21
   PubMed Web of Science ®Google Scholar
• Zaki NM, Nasti A, Tirelli N. (2011). Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model. Macromol Biosci 11:1747–60
   PubMed Web of Science ®Google Scholar
• Zaki NM, Tirelli N. (2010). Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin Drug Deliv 7:895–913
   PubMed Web of Science ®Google Scholar
• Zaki NM, Tirelli N. (2011). Assessment of nanomaterials cytotoxicity and internalization. Methods Mol Biol 695:243–59
   PubMedGoogle Scholar
• Zhang K, Wang Y, Yu A, et al. (2010). Cholic acid-modified dendritic multimolecular micelles and enhancement of anticancer drug therapeutic efficacy. Bioconjug Chem 21:1596–601
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu Y, Jiang X, et al. (2004). Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release 96:135–48
   PubMed Web of Science ®Google Scholar
• Zhang L, Sun M, Guo R, et al. (2006). Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer. J Nanosci Nanotechnol 6:2912–20
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang M, Wang Q, et al. (2007a). 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release 119:153–62
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. (2006a). Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262–70
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. (2006b). Self-assembled nanoparticles of poly(lactide)–Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324:191–8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Huey Lee S, Feng SS. (2007b). Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28:1889–99
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hopper-Borge E, Shen T, et al. (2009). Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 77:993–1001
   PubMed Web of Science ®Google Scholar